We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over.
- Authors
Brandwein, J. M.; Leber, B. F.; Howson-Jan, K.; Schimmer, A. D.; Schuh, A. C.; Gupta, V.; Yee, K. W. L.; Wright, J.; Moore, M.; MacAlpine, K.; Minden, M. D.; NCI CTEP Protocol 6670
- Abstract
Patients aged 60 years and over with previously untreated acute myeloid leukemia were enrolled in a Phase I study combining tipifarnib with standard induction therapy. The regimen consisted of cytarabine 100 mg/m(2)/day continuous intravenous (i.v.) infusion on days 1-7, daunorubicin 60 mg/m(2)/day i.v. push x 3 on days 6-8 and tipifarnib twice daily on days 6-15. Tipifarnib was escalated over four dose levels (200, 300, 400 and 600 mg). Patients achieving complete response (CR) were eligible to receive one consolidation using the same regimen. The following dose-limiting toxicities (DLTs) were identified during induction: dose level I: 2/6 (hyperbilirubinemia, respiratory arrest), level II: 0/3, level III: 0/3 and level IV: 4/10 (one each of diarrhea, neutropenic enterocolitis, arrhythmia and delayed hematologic recovery post-consolidation). There were no DLTs due to delayed hematologic recovery post-induction. Of 22 evaluable patients, there were 10 CR, 2 morphologic leukemia-free state (MLFS), 2 partial remission (PR) and 8 non-responders. Of seven patients with adverse risk cytogenetics, there were four CR/MLFS and one PR. In summary, this regimen was well tolerated and the maximum tolerated dose was not reached, although somewhat more severe gastrointestinal toxicity was seen at dose level IV. Tipifarnib 600 mg b.i.d. is considered the recommended dose for further study using this regimen.
- Subjects
MYELOID leukemia; BONE marrow diseases; CLINICAL trials; INTESTINAL diseases; LEUKEMIA; PATIENTS; ANTINEOPLASTIC agents; COMPARATIVE studies; DAUNOMYCIN; DRUG dosage; DRUG side effects; DRUG toxicity; GASTROINTESTINAL diseases; RESEARCH methodology; MEDICAL cooperation; QUINOLONE antibacterial agents; RESEARCH; EVALUATION research; ACUTE myeloid leukemia; DISEASE remission; CYTARABINE; DISEASE complications
- Publication
Leukemia (08876924), 2009, Vol 23, Issue 4, p631
- ISSN
0887-6924
- Publication type
journal article
- DOI
10.1038/leu.2008.341